# Jeffrey S. Ross

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jeffrey-s-ross-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 62,697 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 114 |
| i10-index | 538 |
| OpenAlex ID | https://openalex.org/A5088559019 |
| ORCID iD | https://orcid.org/0000-0001-8494-2596 |
| Works | 1,451 |

## Researcher papers

Showing 12 of 16.

- [Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden](https://scholariq.org/papers/analysis-of-100-000-human-cancer-genomes-reveals-the-landscape-of-tumor/)
- [Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing](https://scholariq.org/papers/development-and-validation-of-a-clinical-cancer-genomic-profiling-test-based-on/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies](https://scholariq.org/papers/identification-of-new-alk-and-ret-gene-fusions-from-colorectal-and-lung-cancer/)
- [Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors](https://scholariq.org/papers/activation-of-met-via-diverse-exon-14-splicing-alterations-occurs-in-multiple/)
- [Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](https://scholariq.org/papers/pharmacogenomic-predictor-of-sensitivity-to-preoperative-chemotherapy-with/)
- [Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade](https://scholariq.org/papers/targeted-next-generation-sequencing-identifies-markers-of-response-to-pd-1/)
- [Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions](https://scholariq.org/papers/inflammatory-myofibroblastic-tumors-harbor-multiple-potentially-actionable/)
- [Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer](https://scholariq.org/papers/microtubule-associated-protein-tau-a-marker-of-paclitaxel-sensitivity-in-breast/)
- [Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer](https://scholariq.org/papers/immune-activation-and-response-to-pembrolizumab-in-pole-mutant-endometrial/)
- [Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations](https://scholariq.org/papers/characterization-of-298-patients-with-lung-cancer-harboring-met-exon-14-skipping/)
- [Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer](https://scholariq.org/papers/immune-activation-and-benefit-from-avelumab-in-ebv-positive-gastric-cancer/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.